VEGFA and colorectal carcinoma: A combination of selumetinib and vorinostat can inhibit proliferation and spheroid formation, which is associated with an increase in apoptosis, cell cycle arrest, and reduced cellular migration and VEGF-A secretion in CRC cells (Deroanne et al., 2002; Morelli et al., 2012).